Hosted on MSN2mon
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse.
pharmaphorum3d
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
pharmaphorum5y
GSK scores major trial win with potential multiple myeloma blockbuster
GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma. The company announced positive ...
Stockhouse2mon
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK, said: “The compelling overall survival data from the DREAMM-7 trial establish the potential of belantamab mafodotin in combination to significantly extend the lives of patients with multiple ...
Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise
GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.
National Institute for Health and Care Excellence1y
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
ADVANZ Pharma (dexamethasone, lenalidomide) (confidentiality agreement not signed, not participating) Amarox (lenalidomide) (confidentiality agreement not signed, not participating) Amgen (carfilzomib ...
National Institute for Health and Care Excellence11mon
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating) Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating) Bausch & ...